Ascentage Pharma Group International ( AAPG) Q4 2025 Earnings Call March 26, 2026 8:00 AM EDT Good day, everyone, and welcome to Ascentage Pharma's 2025 Annual Results Earnings Call. [Operator ...
Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...
Stocktwits on MSN
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter
ImmunityBio rallied after EU approval of Anktiva, NCCN guideline inclusion and continued expansion across multiple cancer programs. ・Adlai Nortye gained after dosing its first U.S. patient in a global ...
Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...
European regulators have backed RET inhibitor and PD-1 regimens, expanding first line options in advanced lung, thyroid, and ...
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, ...
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapyCompan ...
Researchers from The Institute of Cancer Research and The University of Manchester have created the most comprehensive map of cancer-related genetic mutations to date, analysing data from nearly ...
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results